JAHA:心血管低风险人群24小时中心脉压对心血管事件的预测分析!

2018-02-26 xing.T MedSci原创

由此可见。24小时中心脉压能改善心血管低风险高血压患者的心血管事件预测。

中心血压(BP)是一种很有前景的心血管疾病风险评估指标。在识别心血管高危人群中显著优于传统的危险因素,但对于心血管低风险患者却知之甚少,尽管在这一人群中,中心和外周血压(放大)之间的差异通常更大。近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,这项研究的目的是评估24小时内中心血压对心血管低风险的高血压患者心血管事件预测的影响。

研究人员记录了心血管低风险(系统的冠心病的风险评估≤5%)的高血压患者在临床随访和超过24小时的中心和外周血压。该研究的主要终点是在随访期间发生的心血管事件。为了评估24小时内中心脉压的潜在好处,研究人员采用了Cox比例风险模型分析,并用对比度测试法分析了外周和中心血压的曲线下面积。

该研究纳入了来自波尔多的703名高血压患者。在血压测量的最初24小时后,受试者平均随访112.5±70个月。随访期间研究人员记录到了65次心血管事件。当将外周24小时脉压加入分析时,研究人员发现中心血压与心血管事件显著相关(P=0.0259)。24小时中心脉压曲线下面积明显大于诊室血压曲线下面积(P=0.0296),且相比于外周24小时脉压曲线下面积有明显的优势。

由此可见。24小时中心脉压能改善心血管低风险高血压患者的心血管事件预测。

原始出处:


Antoine Cremer,et al. Twenty‐Four‐Hour Central Pulse Pressure for Cardiovascular Events Prediction in a Low‐Cardiovascular‐Risk Population: Results From the Bordeaux Cohort.JAHA.2018. https://doi.org/10.1161/JAHA.117.008225

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1796965, encodeId=81251e9696566, content=<a href='/topic/show?id=57df221e996' target=_blank style='color:#2F92EE;'>#中心脉压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22179, encryptionId=57df221e996, topicName=中心脉压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu Oct 18 10:21:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725275, encodeId=1aca1e25275e5, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Fri Jun 29 05:21:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643524, encodeId=c9db1643524df, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Mar 28 09:21:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267739, encodeId=458f126e73924, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Feb 28 02:21:00 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1796965, encodeId=81251e9696566, content=<a href='/topic/show?id=57df221e996' target=_blank style='color:#2F92EE;'>#中心脉压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22179, encryptionId=57df221e996, topicName=中心脉压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu Oct 18 10:21:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725275, encodeId=1aca1e25275e5, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Fri Jun 29 05:21:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643524, encodeId=c9db1643524df, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Mar 28 09:21:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267739, encodeId=458f126e73924, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Feb 28 02:21:00 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-06-29 chengjn
  3. [GetPortalCommentsPageByObjectIdResponse(id=1796965, encodeId=81251e9696566, content=<a href='/topic/show?id=57df221e996' target=_blank style='color:#2F92EE;'>#中心脉压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22179, encryptionId=57df221e996, topicName=中心脉压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu Oct 18 10:21:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725275, encodeId=1aca1e25275e5, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Fri Jun 29 05:21:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643524, encodeId=c9db1643524df, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Mar 28 09:21:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267739, encodeId=458f126e73924, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Feb 28 02:21:00 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1796965, encodeId=81251e9696566, content=<a href='/topic/show?id=57df221e996' target=_blank style='color:#2F92EE;'>#中心脉压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22179, encryptionId=57df221e996, topicName=中心脉压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu Oct 18 10:21:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725275, encodeId=1aca1e25275e5, content=<a href='/topic/show?id=e20b101402' target=_blank style='color:#2F92EE;'>#24小时#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1014, encryptionId=e20b101402, topicName=24小时)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447433741908, createdName=chengjn, createdTime=Fri Jun 29 05:21:00 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643524, encodeId=c9db1643524df, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Mar 28 09:21:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267739, encodeId=458f126e73924, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Feb 28 02:21:00 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-02-28 zhaohui6731

相关资讯

JACC:主动脉瓣狭窄病人术后的心肌重塑是可逆的

左室肥大是人类心脏疾病的一个关键发展过程,它是由细胞肥大和细胞外基质扩增(间质纤维化)导致的。本研究的目的旨在评估主动脉瓣狭窄(AS)患者的心肌间质纤维化是否可逆。本研究纳入了181名有临床症状的严重AS患者,并在其进行主动脉瓣置换术(AVR)前进行心超评估AS的严重程度,进行心脏磁共振检查评估心脏容积、功能和纤维化程度,进行生物标志物的检测(包括N-末端B型利钠肽和高敏肌钙蛋白T),最后还进行6

JACC:造血细胞的突变会恶化心衰的预后

近期研究表明,白血病相关基因的体细胞突变可以导致造血干细胞的无性克隆,并且随着年龄的增大,这些突变的淋巴细胞会在血液中积累。这些体细胞突变相关的造血细胞在老年人中更常见,并且与心血管疾病发生的风险相关。本研究的目的旨在评估造血细胞中Tet2基因突变对心衰发生的影响。本研究通过主动脉结扎引起的后负荷诱导小鼠产生心衰,竞争性骨髓移植有Tet2缺陷的细胞来模拟TET2突变的造血细胞,另外,建立特异性在骨

JACC:肺动脉高压相关发病率与患者的死亡风险呈明显相关

一般认为,疾病进展过程中出现肺动脉高压(PAH)是预后不好的征兆,然而,PAH相关发病率与预后的相关性没有在随机临床对照试验中证实。本研究的目的旨在用SERAPHIN 和GRIPHON临床研究的数据评估PAH发病事件对后续死亡风险的影响。在SERAPHIN研究中,出现有PAH事件患者3个月的死亡率要高于无PAH事件患者([HR]: 3.39; 95% [CI]: 1.94-5.92)。在GRIPH

JACC:冠脉搭桥治疗伴有糖尿病和左心功能不全的冠心病患者效果更佳

经皮冠脉介入术(PCI)和冠脉搭桥术(CABG)在多血管冠脉病变(CAD)及糖尿病患者中的应用已经被大量报道,但是这些临床研究大部分均排除了左室功能不全(LVD)的患者。本研究的目的旨在评估PCI或者CABG是否会改善CAD伴糖尿病和LVD患者的预后。本研究的主要终点事件是主要不良心脑血管疾病事件的发生,包括死亡、卒中、心梗和反复的血管再生的复合发生率。结果显示,相比于CABG组患者,PCI组患者

JACC:不同类型二代药物洗脱支架在疗效上有差异吗?

不同药物洗脱支架对阻塞性左主干冠脉疾病(LMCAD)的安全性和有效性的比较鲜有报道。本研究旨在评估比较不同类型的二代药物洗脱支架在LMCAD中的安全性和有效性。本研究纳入了2007-2015年来自三个临床数据库的2692名接受有二代药物洗脱支架治疗的LMCAD患者,其中,1254名患者接受了钴铬依维莫司洗脱支架(CoCr-EES);232名患者接受了生物可降解多聚物药物洗脱支架(BP-BES);6

Diabetes Care:非诺贝特对2型糖尿病患者心血管风险的预测作用!

在一些临床试验结果中显示,非诺贝特治疗并不能降低2型糖尿病(T2DM)患者主要心血管事件(MCVE)的发生率。然而,这些试验报告的治疗效果包括了治疗不良反应的患者和对非诺贝特反应良好的患者。近期,一项发表在杂志Diabetes Care上的研究旨在使用统计建模来评估非诺贝特对个体2型糖尿病患者的预期治疗效果。为了估计个体风险,将5年MCVE作为主要结果的FIELD风险模型在来自ACCORD和SMA